UK GPhC-Registered Pharmacy
Buy Wegovy® Online UK
Semaglutide Weight Loss The only once-weekly weight management injection also approved for cardiovascular risk reduction. Prescribed online by UK-registered clinicians.
Semaglutide Weight Loss The only once-weekly weight management injection also approved for cardiovascular risk reduction. Prescribed online by UK-registered clinicians.
GPhC-registered pharmacy
UK-licensed prescribers
Discreet tracked delivery
Genuine Novo Nordisk product
~21%
average body weight loss
with Wegovy® 7.2 mg STEP UP trial (72 weeks), in addition to a reduced-calorie diet and increased physical activity. ~19–21% weight loss vs ~2–4% with placebo.
with Wegovy® 7.2 mg STEP UP trial (72 weeks), in addition to a reduced-calorie diet and increased physical activity. ~19–21% weight loss vs ~2–4% with placebo.
9 in 10
patients lost ≥5% of body weight
1 in 3
patients lost ≥25% of body weight
Why Wegovy®
Benefits you need to know about
Beyond weight loss, Wegovy® has benefits that set it apart from other treatments — highlighted from the latest clinical evidence.
Protects your heart — independently of weight lost
In the SELECT trial, Wegovy® reduced the risk of major cardiovascular events by 20% relative risk reduction — independent of the amount of weight lost. Wegovy® is the only weight management medicine with a cardiovascular risk reduction indication.
Preserves muscle mass — 84.5% of weight lost is fat
MRI analysis from the STEP UP trial confirmed that 84.5% of weight lost was body fat, not lean muscle. Functional muscle capacity (measured by sit-to-stand test) was fully preserved vs placebo.
No need to change your contraceptive pill
Unlike some other weight loss injections, Wegovy® is not anticipated to reduce the effectiveness of oral contraceptives. No requirement to switch from pill to another contraceptive method.
Clinically meaningful knee pain relief
Wegovy® is the only approved pharmacotherapy to demonstrate a clinically meaningful improvement in knee osteoarthritis-related pain alongside superior weight loss vs placebo over 68 weeks.
Once a week, any time of day
Wegovy® is a pre-filled FlexTouch® pen injected once weekly, independent of meals, at any time of day. Each pen contains four pre-filled doses — one month of treatment in a single pen.
Trusted by over 40 million patients worldwide
More than 40.8 million people worldwide have been treated with semaglutide-containing therapies since 2018. Wegovy® is manufactured by Novo Nordisk and supplied as a genuine, regulated medicine.
MHRA-licensed in the UK
Wegovy® is licensed by the MHRA for weight management in adults with obesity or overweight and weight-related health conditions, and for cardiovascular risk reduction in adults with established CVD.
94% similar to your own GLP-1 hormone
Semaglutide shares 94% sequence similarity with human GLP-1 — the body's natural hormone for regulating appetite and calorie intake. Targets key areas of the brain to reduce hunger and increase fullness.
About the Medicine
What is Wegovy® (semaglutide)?
Wegovy® is a prescription-only weight loss injection containing the active ingredient semaglutide. It is designed to support weight loss and long-term weight management in adults who meet specific clinical criteria.
Wegovy® is taken once weekly using a pre-filled injection pen and is prescribed alongside a reduced-calorie diet and increased physical activity. It belongs to a class of medicines known as GLP-1 receptor agonists (GLP-1 RAs), which mimic a naturally occurring hormone that regulates appetite and calorie intake.
In the UK, Wegovy® is only available following a clinical assessment to ensure it is safe and appropriate for your individual health profile. At Happy Pharmacy, Wegovy® is prescribed by qualified clinicians and dispensed by a UK GPhC-registered pharmacy.
~21%
average body weight loss with 7.2 mg dose
40M+
patients treated with semaglutide worldwide
94%
similarity to your body's own GLP-1 hormone
20%
relative risk reduction in cardiovascular events
GLP-1 receptor agonist
Semaglutide mimics the GLP-1 hormone, targeting key areas of the brain to reduce hunger signals and increase feelings of fullness — supporting sustained weight management alongside diet and lifestyle changes.
Clinical Evidence
Clinically proven Wegovy® results
Wegovy® is backed by the STEP clinical trial programme — the largest weight management trial programme of its kind. Here is what the evidence shows.
What the latest clinical trial showed (2025)
In a large clinical trial over 18 months, people taking the higher-dose Wegovy® 7.2 mg lost an average of 19–21% of their body weight — compared to just 2–4% for those on a placebo. To put that in context, someone starting at 112 kg could expect to lose around 21–23 kg. More than 9 out of 10 patients lost at least 5% of their body weight, and 1 in 3 lost 25% or more.
Standard dose results
At the standard maintenance dose of Wegovy® 2.4 mg, a separate trial over 68 weeks found patients lost an average of 15–17% of their body weight — compared to around 2% with placebo — alongside a reduced-calorie diet and increased physical activity.
Typical weight loss timeline
*Based on average outcomes from STEP 1 clinical trial. Individual results vary. Weight loss should always be achieved alongside a reduced-calorie diet and increased physical activity.
~21%
average body weight loss (STEP UP, 7.2 mg, 72 weeks)
>9/10
patients achieved ≥5% weight loss vs ~4/10 with placebo
1 in 3
patients achieved ≥25% weight loss vs 0% with placebo
20%
relative risk reduction in major cardiovascular events (SELECT trial)
| Treatment stage | Approximate timeframe | Average weight loss observed* |
|---|---|---|
| Initial dose (0.25 mg → 0.5 mg) | Weeks 1–8 | ~2–5% of body weight |
| Dose escalation (1 mg → 1.7 mg) | Weeks 9–16 | ~5–10% of body weight |
| Maintenance dose (2.4 mg) | Weeks 17–68 | ~10–17% of body weight |
Heart Health
Wegovy® and cardiovascular risk reduction
Obesity is a major risk factor for cardiovascular disease (CVD), which affects over 7.6 million people in the UK. More than 2 in 3 patients with a high BMI die from CVD.
Body Composition
Preserving muscle while losing fat
A common concern with weight loss treatments is whether muscle mass is lost alongside fat. The STEP UP trial provides reassuring evidence.
Wegovy® is the only weight management medicine with a cardiovascular risk reduction indication
In the SELECT trial — involving over 17,600 adults with overweight or obesity and established CVD, without diabetes — Wegovy® 2.4 mg reduced the risk of major adverse cardiovascular events by 20% relative risk reduction (1.5% absolute risk reduction) vs placebo, on top of standard of care.
SELECT trial: HR 0.80; 95% CI 0.72–0.90; p<0.001. All patients treated on top of standard of care including CV risk factor management and healthy lifestyle counselling.
20%
relative risk reduction in major cardiovascular events (SELECT trial)
Heart protection works regardless of weight lost
A prespecified analysis of the SELECT trial found that the cardiovascular benefit of Wegovy® was independent of the extent of weight loss — both patients who lost less than 5% and those who lost 5% or more experienced similar cardiovascular protection. This suggests potential mechanisms beyond weight loss alone.
MRI sub-study analysis from the STEP UP trial confirmed that when patients lost weight with Wegovy®, the vast majority of that loss came from body fat, not lean muscle. The small reduction in lean mass was not clinically significant.
Muscle function was assessed using a sit-to-stand test — there were no differences in functional muscle capacity between patients taking Wegovy® and those on placebo.
Am I Eligible?
Who is Wegovy® for?
Wegovy® is prescribed for adults who meet specific clinical criteria based on BMI and overall health. Eligibility is confirmed during your online consultation.
This list is not exhaustive. Final suitability is always confirmed following clinician review during your online consultation. Please refer to the Wegovy® SmPC for full prescribing information.
✓ You may be eligible if…
- BMI of 30 or above (clinically obese)
- BMI of 27 or above with a weight-related health condition (e.g. high blood pressure, high cholesterol, pre-diabetes, diet-controlled type 2 diabetes, sleep apnoea, or heart disease)
- Aged 18 or over
- Not pregnant or breast-feeding
- Able to follow dietary and lifestyle guidance
- Established cardiovascular disease (for CV risk reduction indication)
✗ Wegovy® may not be suitable if…
- You are pregnant, breast-feeding, or trying to conceive
- You have type 1 diabetes
- You are already taking another GLP-1 receptor agonist (e.g. Ozempic®, Mounjaro®)
- You have a history of pancreatitis
- You have a personal or family history of medullary thyroid carcinoma (MTC) or MEN2
- You have severe gastroparesis or severe gastrointestinal disease
- You have a known hypersensitivity to semaglutide or any of its excipients
Women's health
Please note: if you experience severe vomiting or diarrhoea while taking Wegovy®, this could theoretically affect the absorption of any orally taken medicine, including the pill. If this applies to you, follow the pill manufacturer's missed-dose guidance or seek advice from your prescriber or pharmacist.
Pregnancy: Semaglutide should not be used during pregnancy. If you wish to become pregnant, semaglutide must be stopped at least 2 months before a planned pregnancy due to its long half-life.
Breast-feeding: Wegovy® should not be used whilst breast-feeding.
Fertility: The effect of semaglutide on human fertility is currently unknown. Women of childbearing age are recommended to use contraception whilst taking semaglutide.
No need to change your contraceptive pill
Wegovy® does not affect how well the contraceptive pill works. You can continue taking your pill as normal — no switch to another form of contraception is needed. This is not the case with all weight loss injections.
Treatment Plan
Wegovy® dosage and treatment timeline
Wegovy® is started at a low dose and increased gradually over 16 weeks to reach the maintenance dose of 2.4 mg, helping to minimise the likelihood of side effects. For eligible patients with obesity, the dose may be further increased to 7.2 mg.
| Weeks | Dose | What this stage is for | Stage |
|---|---|---|---|
| 1–4 | 0.25 mg once weekly | Starting dose to help your body adjust to treatment | Starter |
| 5–8 | 0.5 mg once weekly | First increase; appetite control may begin to improve further | Titration |
| 9–12 | 1 mg once weekly | Gradual step-up to support continued progress and tolerability | Titration |
| 13–16 | 1.7 mg once weekly | Higher dose for patients who need additional appetite support | Titration |
| 17+ | 2.4 mg once weekly | Standard maintenance dose for ongoing weight management | Maintenance |
| After ≥4 weeks on 2.4 mg | 7.2 mg once weekly (3 × 2.4 mg injections) | Higher dose for people with obesity (BMI ≥30) to achieve up to ~21% weight loss (STEP UP trial) | STEP UP dose |
What if I don't lose enough weight?
If you have been unable to lose at least 5% of your initial body weight after 6 months on the maintenance dose, your prescriber will need to review whether to continue treatment, taking into account your individual benefit-risk profile. Dose increases may be paused or delayed if gastrointestinal side effects occur.
Pricing
How much does Wegovy® cost in the UK?
Each Wegovy® FlexTouch® pen contains four once-weekly doses — one month of treatment. Prices vary by dose. Higher strengths cost more as treatment progresses.
Prices are for the Wegovy® FlexTouch® pen only. Consultation fee may apply. Supplied only where clinically appropriate following prescriber assessment. Pricing is subject to change.
0.25 mg
once weekly
Weeks 1–4
£89.99
4-week pen
0.5 mg
once weekly
Weeks 5–8
£110.99
4-week pen
1 mg
once weekly
Weeks 9–12
£129.99
4-week pen
1.7 mg
once weekly
Weeks 13–16
£159.99
4-week pen
Maintenance
2.4 mg
once weekly
Week 17+
£194.99
4-week pen
Device
- Wegovy® FlexTouch® pen (prescribed dose)
- 4 disposable NovoFine Plus needles
- Alcohol wipes & sharps bin
Delivery
- Discreet, plain packaging
- Temperature-controlled where required
- Tracked delivery on all orders
Clinical Support
- Online prescriber consultation
- Patient guidance leaflet
- Ongoing pharmacist & prescriber support
Using Your Pen
How to use the Wegovy® FlexTouch® pen
Wegovy® is a pre-filled, multi-dose injection pen designed for once-weekly use. It is injected on the same day each week, at any time of day, with or without food. Most people find the pen simple to use after initial guidance.
1
Wash hands & prepare
Wash your hands thoroughly. Take your Wegovy® FlexTouch® pen from the fridge and allow it to warm slightly.
2
Attach a new needle
Use a new NovoFine Plus needle for each injection. Never reuse needles.
3
Choose your injection area
Inject into the abdomen (at least 5 cm from the navel), upper thigh, or upper arm (if someone else is injecting).
4
Rotate sites weekly
Always rotate injection sites and leave at least one finger-width between spots to avoid skin irritation.
5
Clean skin & check dose
Clean the skin with an alcohol wipe, allow to dry, and confirm the correct prescribed dose is selected on the pen.
6
Inject & hold
Inject as instructed and hold the pen in place for several seconds to ensure the full dose is delivered.
7
Dispose safely
Remove the needle and place it immediately in your sharps container. Replace the pen cap.
8
Record your dose
Note the date and dose taken. Wegovy® is given once weekly — try to inject on the same day each week.
9
Store correctly
Store unused pens in the fridge (2–8°C). Once in use, the pen may be kept below 30°C for up to 6 weeks. Do not freeze.
FlexTouch® pen recycling
Used FlexTouch® pens can be recycled through the Novo Nordisk PenCycle™ scheme — a free recycling programme to help reduce pharmaceutical waste. Visit the Novo Nordisk PenCycle portal for details.
Safety Information
Wegovy® side effects
Like all prescription medicines, Wegovy® can cause side effects — but most are mild to moderate and improve over time, particularly during dose escalation. This information does not replace the full SmPC or your prescriber's advice.
⚠ Very common side effects (≥1 in 10 patients)
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal pain
- Headache
- Fatigue
⚠ Common side effects (1–10 in 100 patients)
- Dizziness, dysgeusia (altered taste)
- Gastritis, indigestion, heartburn, bloating
- Hair loss
- Injection site reactions
- Gallstones (cholelithiasis)
- Hypoglycaemia (in patients with type 2 diabetes)
- Diabetic retinopathy (in patients with type 2 diabetes)
Serious / uncommon adverse reactions — seek urgent medical advice
For urgent symptoms, contact NHS 111. For emergencies (difficulty breathing, collapse), call 999. For the full list of adverse reactions, refer to the Wegovy® SmPC. Adverse events should be reported to the MHRA via the Yellow Card scheme or to Novo Nordisk on 0800 023 2573.
- Acute pancreatitis (uncommon): persistent, severe abdominal pain — stop treatment and seek urgent help
- Severe allergic reaction / anaphylaxis (rare): swelling of face, lips, throat, or difficulty breathing
- Kidney or bladder stones (uncommon)
- Hip fractures (rare): more common in women and those aged 75+
- NAION (very rare): sudden visual disturbance — seek urgent ophthalmology review
- Bowel obstruction (frequency unknown)
FAQs
Frequently asked questions
Clinical trials show an average weight loss of approximately 15–17% with Wegovy® 2.4 mg (STEP 1, 68 weeks) and approximately 19–21% with the higher Wegovy® 7.2 mg dose (STEP UP, 72 weeks), both in addition to a reduced-calorie diet and increased physical activity. Individual results vary. Over 9 in 10 patients achieved at least 5% weight loss, and around 1 in 3 achieved 25% or more.
No. Wegovy® is not anticipated to reduce the effectiveness of oral contraceptives. The SmPC contains no requirement to switch from the pill to another form of contraception. However, if you experience severe vomiting or diarrhoea, this could affect pill absorption, so follow your pill's missed-dose guidance or seek pharmacist advice.
Clinical evidence from the STEP UP trial shows that 84.5% of weight lost on Wegovy® comes from body fat, not lean muscle. The small reduction in lean body mass observed was not clinically significant. Crucially, functional muscle capacity — measured by a sit-to-stand test — was fully preserved compared to placebo.
The 2.4 mg weekly dose is the standard maintenance dose and is suitable for weight management and cardiovascular risk reduction. The 7.2 mg weekly dose (given as three 2.4 mg injections) is a higher dose for adults with obesity (BMI ≥30) that may be prescribed after at least 4 weeks on 2.4 mg — the STEP UP trial showed it achieved approximately 19–21% weight loss at 72 weeks.
Wegovy® is the only weight management medicine with a cardiovascular risk reduction indication — it is specifically indicated to reduce the risk of major cardiovascular events in adults with established CVD and obesity or overweight (BMI ≥27). Discuss your full cardiovascular history with your prescriber during your consultation.
Wegovy® is a prescription-only medicine (POM) in the UK and must only be purchased from a GPhC-registered pharmacy following a clinician-approved consultation. At Happy Pharmacy, your consultation is reviewed by a UK-registered prescriber. Never buy Wegovy® from unregulated websites or social media sellers — counterfeit products carry serious health risks.
Wegovy® contains semaglutide and targets the GLP-1 receptor. Mounjaro® (tirzepatide) targets both GLP-1 and GIP receptors (a dual agonist), which may produce greater weight loss for some patients. Both are prescription injections used alongside diet and lifestyle changes. Your Happy Pharmacy prescriber can advise which is more appropriate for your individual health profile.
ResourcesDownload Information FilesDownload our patient information leaflets, clinical summaries and prescribing guides.
Wegovy® FactsheetKey Information about Wegovy.
Wegovy® BrochureGuidance and information for adultswho have been prescribed Wegovy®for weight management